Cargando…

Budesonide-Loaded Bilosomes as a Targeted Delivery Therapeutic Approach Against Acute Lung Injury in Rats

Budesonide (BUD), a glucocorticoids drug, inhibits all steps in the inflammatory response. It can reduce and treat inflammation and other symptoms associated with acute lung injury such as COVID-19. Loading BUD into bilosomes could boost its therapeutic activity, and lessen its frequent administrati...

Descripción completa

Detalles Bibliográficos
Autores principales: Salem, Heba F., Moubarak, Ghada Abdelsabour, Ali, Adel A., Salama, Abeer A.A., Salama, Alaa H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. on behalf of American Pharmacists Association. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549718/
https://www.ncbi.nlm.nih.gov/pubmed/36228754
http://dx.doi.org/10.1016/j.xphs.2022.10.001
_version_ 1784805732280958976
author Salem, Heba F.
Moubarak, Ghada Abdelsabour
Ali, Adel A.
Salama, Abeer A.A.
Salama, Alaa H.
author_facet Salem, Heba F.
Moubarak, Ghada Abdelsabour
Ali, Adel A.
Salama, Abeer A.A.
Salama, Alaa H.
author_sort Salem, Heba F.
collection PubMed
description Budesonide (BUD), a glucocorticoids drug, inhibits all steps in the inflammatory response. It can reduce and treat inflammation and other symptoms associated with acute lung injury such as COVID-19. Loading BUD into bilosomes could boost its therapeutic activity, and lessen its frequent administration and side effects. Different bilosomal formulations were prepared where the independent variables were lipid type (Cholesterol, Phospholipon 80H, L-alpha phosphatidylcholine, and Lipoid S45), bile salt type (Na cholate and Na deoxycholate), and drug concentration (10, 20 mg). The measured responses were: vesicle size, entrapment efficiency, and release efficiency. One optimum formulation (composed of cholesterol, Na cholate, and 10 mg of BUD) was selected and investigated for its anti-inflammatory efficacy in vivo using Wistar albino male rats. Randomly allocated rats were distributed into four groups: The first: normal control group and received intranasal saline, the second one acted as the acute lung injury model received intranasal single dose of 2 mg/kg potassium dichromate (PD). Whereas the third and fourth groups received the market product (Pulmicort® nebulising suspension 0.5 mg/ml) and the optimized formulation (0.5 mg/kg; intranasal) for 7 days after PD instillation, respectively. Results showed that the optimized formulation decreased the pro-inflammatory cytokines TNF-α, and TGF-β contents as well as reduced PKC content in lung. These findings suggest the potentiality of BUD-loaded bilosomes for the treatment of acute lung injury with the ability of inhibiting the pro-inflammatory cytokines induced COVID-19.
format Online
Article
Text
id pubmed-9549718
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Published by Elsevier Inc. on behalf of American Pharmacists Association.
record_format MEDLINE/PubMed
spelling pubmed-95497182022-10-11 Budesonide-Loaded Bilosomes as a Targeted Delivery Therapeutic Approach Against Acute Lung Injury in Rats Salem, Heba F. Moubarak, Ghada Abdelsabour Ali, Adel A. Salama, Abeer A.A. Salama, Alaa H. J Pharm Sci Pharmaceutics, Drug Delivery and Pharmaceutical Technology Budesonide (BUD), a glucocorticoids drug, inhibits all steps in the inflammatory response. It can reduce and treat inflammation and other symptoms associated with acute lung injury such as COVID-19. Loading BUD into bilosomes could boost its therapeutic activity, and lessen its frequent administration and side effects. Different bilosomal formulations were prepared where the independent variables were lipid type (Cholesterol, Phospholipon 80H, L-alpha phosphatidylcholine, and Lipoid S45), bile salt type (Na cholate and Na deoxycholate), and drug concentration (10, 20 mg). The measured responses were: vesicle size, entrapment efficiency, and release efficiency. One optimum formulation (composed of cholesterol, Na cholate, and 10 mg of BUD) was selected and investigated for its anti-inflammatory efficacy in vivo using Wistar albino male rats. Randomly allocated rats were distributed into four groups: The first: normal control group and received intranasal saline, the second one acted as the acute lung injury model received intranasal single dose of 2 mg/kg potassium dichromate (PD). Whereas the third and fourth groups received the market product (Pulmicort® nebulising suspension 0.5 mg/ml) and the optimized formulation (0.5 mg/kg; intranasal) for 7 days after PD instillation, respectively. Results showed that the optimized formulation decreased the pro-inflammatory cytokines TNF-α, and TGF-β contents as well as reduced PKC content in lung. These findings suggest the potentiality of BUD-loaded bilosomes for the treatment of acute lung injury with the ability of inhibiting the pro-inflammatory cytokines induced COVID-19. Published by Elsevier Inc. on behalf of American Pharmacists Association. 2023-03 2022-10-10 /pmc/articles/PMC9549718/ /pubmed/36228754 http://dx.doi.org/10.1016/j.xphs.2022.10.001 Text en © 2022 Published by Elsevier Inc. on behalf of American Pharmacists Association. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Pharmaceutics, Drug Delivery and Pharmaceutical Technology
Salem, Heba F.
Moubarak, Ghada Abdelsabour
Ali, Adel A.
Salama, Abeer A.A.
Salama, Alaa H.
Budesonide-Loaded Bilosomes as a Targeted Delivery Therapeutic Approach Against Acute Lung Injury in Rats
title Budesonide-Loaded Bilosomes as a Targeted Delivery Therapeutic Approach Against Acute Lung Injury in Rats
title_full Budesonide-Loaded Bilosomes as a Targeted Delivery Therapeutic Approach Against Acute Lung Injury in Rats
title_fullStr Budesonide-Loaded Bilosomes as a Targeted Delivery Therapeutic Approach Against Acute Lung Injury in Rats
title_full_unstemmed Budesonide-Loaded Bilosomes as a Targeted Delivery Therapeutic Approach Against Acute Lung Injury in Rats
title_short Budesonide-Loaded Bilosomes as a Targeted Delivery Therapeutic Approach Against Acute Lung Injury in Rats
title_sort budesonide-loaded bilosomes as a targeted delivery therapeutic approach against acute lung injury in rats
topic Pharmaceutics, Drug Delivery and Pharmaceutical Technology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549718/
https://www.ncbi.nlm.nih.gov/pubmed/36228754
http://dx.doi.org/10.1016/j.xphs.2022.10.001
work_keys_str_mv AT salemhebaf budesonideloadedbilosomesasatargeteddeliverytherapeuticapproachagainstacutelunginjuryinrats
AT moubarakghadaabdelsabour budesonideloadedbilosomesasatargeteddeliverytherapeuticapproachagainstacutelunginjuryinrats
AT aliadela budesonideloadedbilosomesasatargeteddeliverytherapeuticapproachagainstacutelunginjuryinrats
AT salamaabeeraa budesonideloadedbilosomesasatargeteddeliverytherapeuticapproachagainstacutelunginjuryinrats
AT salamaalaah budesonideloadedbilosomesasatargeteddeliverytherapeuticapproachagainstacutelunginjuryinrats